What is the price targets for biorestorative therapies (brtx) stock?
Their BRTX stock forecasts range from $37.00 to $37.00. On average, they predict BioRestorative Therapies' share price to reach $37.00 in the next year. This suggests a possible upside of 1,141.6% from the stock's current price. View analysts' price targets for BioRestorative Therapies or view top-rated stocks among Wall Street analysts.
What is the price targets for bntx?
The high price target for BNTX is $105.00 and the low price target for BNTX is $21.00. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
What is the price target for biontech stock?
The average twelve-month price target for BioNTech is $288.43 with a high price target of $433.00 and a low price target of $146.00. Learn more Do Wall Street analysts like BioNTech more than its competitors? Analysts like BioNTech stock less than the stock of other Medical companies.
What is a strong Buy rating on Wall Street?
Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts.
Will BRTX stock go up?
Based on our forecasts, a long-term increase is expected, the "BRTX" stock price prognosis for 2027-06-30 is 4.338 USD. With a 5-year investment, the revenue is expected to be around +26.1%. Your current $100 investment may be up to $126.1 in 2027.
Where can I buy BRTX?
Shares of BRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Is BRTX a good investment?
BioRestorative Therapies Inc (NASDAQ:BRTX) The 1 analysts offering 12-month price forecasts for BioRestorative Therapies Inc have a median target of 37.00, with a high estimate of 37.00 and a low estimate of 37.00. The median estimate represents a +1,101.30% increase from the last price of 3.08.
What is BioRestorative Therapies's consensus rating and price target?
According to the issued ratings of 1 analysts in the last year, the consensus rating for BioRestorative Therapies stock is Buy based on the current...
Do Wall Street analysts like BioRestorative Therapies more than its competitors?
Analysts like BioRestorative Therapies stock more than the stock of other Medical companies. The consensus rating score for BioRestorative Therapie...
Do MarketBeat users like BioRestorative Therapies more than its competitors?
MarketBeat users like BioRestorative Therapies stock more than the stock of other Medical companies. 73.85% of MarketBeat users gave BioRestorative...
Does BioRestorative Therapies's stock price have much upside?
According to analysts, BioRestorative Therapies's stock has a predicted upside of 516.67% based on their 12-month price targets.
Should I buy or sell BioRestorative Therapies stock right now?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioRestorative Therapies in the last twelve months. There are currently 1...
What is BioRestorative Therapies' stock price forecast for 2022?
1 brokerages have issued twelve-month price targets for BioRestorative Therapies' shares. Their forecasts range from $37.00 to $37.00. On average,...
How has BioRestorative Therapies' stock performed in 2022?
BioRestorative Therapies' stock was trading at $4.34 at the beginning of 2022. Since then, BRTX stock has decreased by 3.5% and is now trading at $...
When did BioRestorative Therapies' stock split? How did BioRestorative Therapies' stock split work?
Shares of BioRestorative Therapies reverse split on the morning of Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesda...
Who are BioRestorative Therapies' key executives?
BioRestorative Therapies' management team includes the following people: Mr. Lance Alstodt , Chairman, Pres & CEO (Age 51, Pay $275k) ( LinkedIn...
Who are some of BioRestorative Therapies' key competitors?
Some companies that are related to BioRestorative Therapies include Cryo-Cell International (CCEL) , Greenbrook TMS (GBNH) , Caladrius Bioscienc...
What other stocks do shareholders of BioRestorative Therapies own?
Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include Co-Diagnost...
What is BioRestorative Therapies' stock symbol?
BioRestorative Therapies trades on the OTCMKTS under the ticker symbol "BRTX."
Who are BioRestorative Therapies' major shareholders?
BioRestorative Therapies' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc...
What is the ticker symbol for BioRestorative Therapies?
BioRestorative Therapies trades on the OTCMKTS under the ticker symbol "BRTX."
What is marketbeat community ratings?
MarketBeat's community ratings are surveys of what our community members think about BioRestorative Therapies and other stocks. Vote “Outperform” if you believe BRTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
What is the official website for biorestorative therapy?
The official website for BioRestorative Therapies is www.biorestorative.com.
What is biorestorative therapy?
Biorestorative Therapies Inc. provides stem cell collections, storage, and treatment services. It intends to develop a laboratory, performing cellular characterization and culturing, therapeutic outcomes analysis, stem cell-related IP and stem cell collection and storage services. The firm is developing the following scientific programs: brtxDISC, which offers a non-surgical treatment for bulging and herniated discs and addresses the gap between non-invasive and invasive back procedures; and ThermoStem, which involves in the use of a cell-based, brown adipose tissue construct, treatment for metabolic disease, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. Its products are sold under the BRTX-100, ThermoStem and Stem Pearls as its trademarks. The company was founded on June 13, 1997 and is headquartered in Melville, NY.
When will BioRestorative Therapies reverse split?
Shares of BioRestorative Therapies reverse split on Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 27th 2021. An investor that had 100 shares of BioRestorative Therapies stock prior to the reverse split would have 0 shares after the split.
Where is BioRestorative Therapies located?
BioRestorative Therapies' mailing address is 40 MARCUS DRIVE, MELVILLE NY, 11747. The company can be reached via phone at (631) 760-8100 or via email at [email protected].
Does BioRestorative Therapies pay dividends?
BioRestorative Therapies does not currently pay a dividend.
When will BRTX stock start trading?
Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol “BRTX” November 5, 2021 MELVILLE, N.Y., Nov. 04, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced the pricing of the underwritten public offering of 2,300,000 units, each consisting of one share of its common stock and a warrant to purchase one share of its common stock at a per unit price of
What is BRTX 100?
In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery.
When will the company file its 10Qs?
The Company expects to file its 2020 Form 10-Qs by early April 2021 and its Annual Report on Form 10-K for the year ended December 31, 2020 in April 2021. Upon making such filings with the SEC, the Company will be current in its SEC filings.
When is BRTX meeting 2021?
MELVILLE, N.Y., Aug. 11, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today reminded its stockholders that its annual meeting of stockholders will be held on Tuesday, August 17, 2021 at 10 a.m. EDT. Lance Alstodt, President and Chief Executive Officer of the Company, stated “At the stockholders meeting, certain proposals, including the approval of our reincorporation from Del
When did BioRestorative go bankrupt?
BioRestorative filed for Chapter 11 bankruptcy protection on March 20, 2020 and emerged on November 16, 2020 with a confirmed plan of reorganization.
Is BRTX a patent?
(the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Japanese Patent Office has issued the Company a patent related to its metabolic ThermoStem® Program. Claims granted under the new patent cover methodologies related to brown adipocytes from human b
BioRestorative Therapies Inc Stock Forecast
Over the next 52 weeks, BioRestorative Therapies Inc has on average historically risen by 399 % based on the past 13 years of stock performance.
Will BioRestorative Therapies Inc Stock Go Up Next Year?
Over the next 52 weeks, BioRestorative Therapies Inc has on average historically risen by 399% based on the past 13 years of stock performance.
BioRestorative Therapies Inc Stock Price History
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and BRTX is experiencing buying pressure, which is a positive indicator for future bullish movement.
Stock Predictions
Is BioRestorative Therapies Inc stock public? Yes, BioRestorative Therapies Inc is a publicly traded company.
BriaCell Therapeutics (NASDAQ:BCTX) Price Target and Consensus Rating
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Price Target Consensus
Sign-up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter.
Analyst Ratings By Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Average Share Price and Price Target by Month
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
How does MarketBeat calculate stock ratings?
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
What does the blue line on the chart below mean?
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
How does MarketBeat calculate stock ratings?
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
What does the blue line on the chart below mean?
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Does MarketBeat like Biontech?
MarketBeat users like BioNTech stock less than the stock of other Medical companies. 54.19% of MarketBeat users gave BioNTech an outperform vote while medical companies recieve an average of 67.31% outperform votes by MarketBeat users.
